Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two‐year outcomes after the study closure
Vittorio Pengo, Ariela Hoxha, Laura Andréoli, Anǵela Tincani, Elena Silvestri, Domenico Prisco, Tiziana Fierro, Paolo Gresele, Arturo Cafolla, Valeria Micheli, Angelo Ghirarduzzi, Alberto Tosetto, Anna Falanga, Ida Martinelli, Sophie Testa, Doris Barcellona, Maria Gerosa, Gentian Denas
Topics & Concepts
RivaroxabanMedicineWarfarinHazard ratioAntiphospholipid syndromeRandomized controlled trialConfidence intervalInternal medicineDabigatranThrombosisSurgeryAtrial fibrillationSystemic Lupus Erythematosus ResearchAtrial Fibrillation Management and OutcomesBlood Coagulation and Thrombosis Mechanisms